CymaBay Therapeutics Inc (NASDAQ:CBAY) Director Carl Goldfischer sold 11,675 shares of CymaBay Therapeutics stock in a transaction dated Thursday, February 7th. The stock was sold at an average price of $9.02, for a total value of $105,308.50. Following the sale, the director now owns 2,335 shares of the company’s stock, valued at approximately $21,061.70. The transaction was disclosed in a document filed with the SEC, which is available at this link.
CymaBay Therapeutics stock opened at $9.27 on Monday. CymaBay Therapeutics Inc has a 52 week low of $6.31 and a 52 week high of $15.59.
A number of analysts recently commented on CBAY shares. Zacks Investment Research cut CymaBay Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, October 15th. BidaskClub upgraded CymaBay Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, November 2nd. Cantor Fitzgerald set a $17.00 price objective on CymaBay Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, November 7th. Oppenheimer set a $18.00 price objective on CymaBay Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, November 7th. Finally, HC Wainwright reiterated a “buy” rating on shares of CymaBay Therapeutics in a research report on Monday, November 19th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $18.89.
WARNING: This report was reported by Dakota Financial News and is the sole property of of Dakota Financial News. If you are viewing this report on another domain, it was illegally copied and reposted in violation of US & international trademark & copyright legislation. The legal version of this report can be accessed at https://dakotafinancialnews.com/2019/02/11/cymabay-therapeutics-inc-cbay-director-sells-105308-50-in-stock.html.
About CymaBay Therapeutics
CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis.
See Also: Systematic Risk
Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.